ROHTO-MENTHOLATUM (VIETNAM) CO., LTD

ROHTO-MENTHOLATUM (VIETNAM) CO., LTD (Công ty TNHH Rohto-Mentholatum Việt Nam) has grown into one of Vietnam’s most recognizable names in skincare, eye care, and consumer products in the pharmaceutical sector. With more than 17 years of operations in the VSIP Industrial Park in Bình Dương, the company benefits from strong Japanese ownership, large-scale manufacturing capacity, and a nationwide network of offices in Hồ Chí Minh, Hà Nội, and Đà Nẵng. Its portfolio of health and cosmetic products enjoys strong brand loyalty in Vietnam’s fast-growing beauty and OTC healthcare market.

Legally, the company operates as a wholly foreign-owned limited liability entity under Business ID 3700239769, with over USD 10 million in charter capital and approximately 1,000 employees. All registrations and compliance requirements are in good standing. The sole shareholder is its Japanese parent company, ensuring consistent capital support, technology transfer, and adherence to global production standards. The company’s broad scope of licensed business activities—ranging from pharmaceuticals to skincare and medical supplies—gives it flexibility to diversify product lines and respond to changes in consumer health trends.

The management team, led by its chairman and general director, oversees a highly structured organization that reflects Japanese governance standards. The leadership approach emphasizes product quality, regulatory compliance, and market expansion. Still, a notable challenge is balancing corporate-level efficiency with Vietnam’s increasingly competitive cosmetics and healthcare landscape, where Korean, European, and domestic brands are rapidly gaining ground. Maintaining innovation speed while navigating pricing pressures remains a crucial factor for sustainable growth.

Financially, ROHTO Vietnam demonstrates strength but also exposes a few critical weaknesses. Total assets grew steadily to USD 73.87 million in 2023, while equity increased to USD 59.36 million—solid indicators of long-term capital investment. Sales also climbed to USD 97.39 million, showing continued market demand. However, profitability tells a different story: after a sharp rise in 2022, profit fell by 27.45% in 2023, dropping to USD 5.52 million. This decline signals rising production costs, higher marketing spend, or increased competition, all of which are affecting margins. The downward profit trend, despite revenue growth, suggests the company may need to recalibrate pricing strategies, optimize cost structures, or innovate faster to protect earnings.

Overall, ROHTO-MENTHOLATUM (VIETNAM) remains a financially solid and operationally mature FDI manufacturer, but its recent profit contraction highlights the pressure facing global consumer-health brands in Vietnam. Sustained investment in product innovation, supply-chain efficiency, and market differentiation will be essential if the company wants to maintain its long-term leadership position.